In Situ Programming of CAR Macrophages via mRNA-LNP: Advances in Immunotherapy for Peritoneal Metastasis

Study Background and Research Question

Peritoneal metastasis from solid tumors remains a major clinical challenge, with current interventions like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) benefiting only a minority of patients with minimal tumor burdens (source: paper). The immunosuppressive nature of the peritoneal tumor microenvironment (TME) and the limited efficacy of established immunotherapies in this context underscore the urgent need for novel strategies. Macrophages, which constitute approximately 45% of immune cells in peritoneal ascites, are an attractive target for reprogramming due to their abundance and functional plasticity (source: paper). The central research question addressed by Gu et al. is whether in situ programming of chimeric antigen receptor macrophages (CAR-Ms) via a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) platform can enhance antitumor immunity and improve therapeutic outcomes for peritoneal metastasis.

Key Innovation from the Reference Study

The principal innovation reported by Gu et al. is the development and application of a macrophage-targeted mRNA-LNP delivery system capable of in situ reprogramming resident peritoneal macrophages into tailored CAR-Ms (source: paper). Notably, the study undertakes a systematic screen of 36 CAR intracellular domain (ICD) formats to optimize macrophage activation and antitumor function. Of particular significance is the identification of CAR constructs incorporating CD3ζ and TLR4 ICDs, which synergistically drive robust adaptive immune responses and enhance sensitivity to PD-1/L1 checkpoint blockade. This approach enables a local, non-viral, and flexible method for programming immune effector cells directly within the tumor environment.

Methods and Experimental Design Insights

Gu et al. engineered and validated a set of mRNA-LNP constructs encoding CARs with diverse ICD combinations. The LNPs were tuned for macrophage selectivity, leveraging surface ligands and optimized physicochemical properties. The study employed both in vitro and in vivo models: murine peritoneal metastasis models were used for functional validation, while single-cell RNA sequencing (scRNA-seq) provided high-resolution profiling of immune cell populations and TME changes post-treatment. Key methodological strengths include:

• Systematic CAR library screening: 36 CAR-M formats were tested for functional efficacy and immune activation (source: paper).
• In situ delivery: mRNA-LNPs were administered intraperitoneally, directly programming peritoneal macrophages without ex vivo manipulation.
• Mechanistic dissection: scRNA-seq was used to analyze shifts in immune landscape, including T cell phenotypes and macrophage polarization states.
• Combination therapy: Efficacy of CAR-Ms was assessed in the context of PD-1/L1 blockade, reflecting clinically relevant immunotherapy strategies.

Protocol Parameters

• assay | scRNA-seq profiling | 10,000 cells/sample | peritoneal immune landscape mapping | enables high-resolution analysis of TME shifts post-CAR-M programming | paper
• assay | mRNA-LNP dose | 0.5-1 mg/kg (mouse) | in vivo CAR-M programming | optimal for effective macrophage transfection and safety | paper
• assay | CAR-M/PD-1 blockade combination | anti-PD-1 at 10 mg/kg (mouse) | synergy testing | assesses combinatorial efficacy in modulating tumor growth | paper
• assay | bioluminescence imaging (BLI) | D-Luciferin sodium salt, 150 mg/kg (mouse) | longitudinal tumor monitoring | sensitive readout for tumor burden in vivo | workflow_recommendation
• assay | in vitro phagocytosis assay | E:T ratio 1:1 to 5:1 | CAR-M activity quantification | evaluates functional antitumor capacity | workflow_recommendation

Core Findings and Why They Matter

The study demonstrates that tailored CAR-Ms programmed in situ via mRNA-LNPs significantly inhibit peritoneal tumor growth and prolong survival in murine models (source: paper). Mechanistically, CAR-Ms with CD3ζ and TLR4 ICDs induce a proinflammatory macrophage phenotype, upregulate MHC-I and PD-L1, and disrupt NF-κB signaling pathways. scRNA-seq reveals these interventions increase the population of TCF1+PD-1+ progenitor-exhausted CD8+ T cells (Tpex), which are critical for sustained antitumor immunity and responsiveness to checkpoint therapy. Importantly, the CAR-M/mRNA-LNP system synergizes with PD-1/L1 blockade, overcoming immune suppression in the TME and promoting durable tumor control. These findings suggest a viable strategy for leveraging innate and adaptive immunity against advanced peritoneal malignancies.

Comparison with Existing Internal Articles

Several internal articles provide complementary perspectives on the methodologies and reagents supporting bioluminescence-based cell tracking and metabolic assessment. For instance, "D-Luciferin Sodium Salt: Precision Tools for Quantitative..." discusses how D-Luciferin sodium salt enables robust, ATP-dependent bioluminescence assays for cell viability and metabolism, which are essential for in vivo tumor monitoring in CAR-M studies (source: internal). Similarly, "D-Luciferin Sodium Salt: Benchmark Bioluminescent Substra..." highlights the specificity and high solubility of D-Luciferin sodium salt as a firefly luciferase substrate, facilitating precise non-invasive imaging in oncology models (source: internal). These resources underscore the importance of validated bioluminescent substrates for reliable assessment of tumor progression and therapeutic efficacy, as implemented in the reference study.

Limitations and Transferability

While the mRNA-LNP platform for in situ CAR-M programming presents a compelling translational opportunity, several limitations warrant consideration. First, the data are derived from preclinical murine models, and the immunological complexity in human peritoneal metastasis may present additional barriers (source: paper). Second, the long-term persistence, safety, and regulatory aspects of repeated mRNA-LNP administration remain to be fully elucidated. Third, while the study systematically investigates ICD combinations, the generalizability of these findings to other tumor types or microenvironments will require further validation. Nonetheless, the integration of high-throughput functional screening, mechanistic dissection, and combinatorial immunotherapy highlights a blueprint for optimizing cell-based therapies in challenging metastatic settings.

Research Support Resources

For researchers aiming to replicate or build upon intraperitoneal CAR-M programming workflows, validated reagents for longitudinal cell viability and metabolism monitoring are essential. D-Luciferin sodium salt (SKU B8311) from APExBIO serves as a gold-standard firefly luciferase substrate, supporting sensitive ATP-dependent bioluminescence imaging in preclinical oncology models and facilitating quantitative assessment of tumor burden and immune cell activity (source: internal). For optimal performance, D-Luciferin sodium salt should be freshly prepared and used promptly, following storage guidelines to maintain assay reliability. These resources enable reproducible, data-driven evaluation of experimental immunotherapies in line with the methodologies reported by Gu et al.